专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL284279D0 Saponin conjugated to epitope-binding proteins 未知
公开(公告)号：IL284279D0
公开(公告)日：2021-08-31
申请号：IL28427921
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

2. 发明专利

IL284273D0 Antibody drug conjugates (adc) containing saponin 未知
公开(公告)号：IL284273D0
公开(公告)日：2021-08-31
申请号：IL28427321
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

3. 发明专利

IL284280D0 Improved antibody-oligonucleotide conjugate 未知
公开(公告)号：IL284280D0
公开(公告)日：2021-08-31
申请号：IL28428021
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

4. 发明专利

IL284274D0 Antibody-drug conjugate with improved therapeutic window 未知
公开(公告)号：IL284274D0
公开(公告)日：2021-08-31
申请号：IL28427421
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

5. 发明专利

IL290060D0 Saponin derivatives with improved therapeutic window 未知
公开(公告)号：IL290060D0
公开(公告)日：2022-03-01
申请号：IL29006022
申请日：2022-01-23
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , GUY HERMANS , HENDRIK FUCHS
发明人： RUBEN POSTEL , GUY HERMANS , HENDRIK FUCHS
IPC分类号： C07H15/256 , C07J63/00
摘要： The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention. In addition, the invention relates to a pharmaceutical combination comprising the first pharmaceutical composition of the invention and a second pharmaceutical composition comprising any one or more of an antibody-toxin conjugate, a receptor-ligand – toxin conjugate, an antibody-drug conjugate, a receptor-ligand – drug conjugate, an antibody-oligonucleotide conjugate or a receptor-ligand – oligonucleotide conjugate. The invention also relates to the first pharmaceutical composition or the pharmaceutical combination of the invention, for use as a medicament, or use in the treatment or prophylaxis of a cancer, an infectious disease, viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis, or an auto-immune disease. Furthermore, the invention relates to an in vitro or ex vivo method for transferring a molecule from outside a cell to inside said cell, comprising contacting said cell with the molecule and with a saponin derivative of the invention.

6. 发明专利

IL284278D0 Saponin conjugates 未知
公开(公告)号：IL284278D0
公开(公告)日：2021-08-31
申请号：IL28427821
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

7. 发明专利

IL284265D0 Biologically active cluster of molecules 未知
公开(公告)号：IL284265D0
公开(公告)日：2021-08-31
申请号：IL28426521
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

8. 发明授权

US5511093A Method for reducing data in a multi-channel data transmission 失效
标题翻译：减少多通道数据传输中数据的方法
公开(公告)号：US5511093A
公开(公告)日：1996-04-23
申请号：US238107
申请日：1994-05-04
申请人： Bernd Edler , Hendrik Fuchs
发明人： Bernd Edler , Hendrik Fuchs
IPC分类号： H03M7/30 , G10L19/00 , H03H17/00 , H03H17/02 , H04B1/66 , H04B14/04 , H04H20/42 , H04H60/07 , H04N7/26 , H04N7/32 , H04N7/34 , H04N7/52 , H04N7/12
CPC分类号： H04H60/07 , G10L19/008 , H04B1/665 , H04B14/046 , H04H20/42 , H04N19/00 , H04N19/50 , H04N19/593
摘要： In a method for reducing data in a multi-channel data transmission, existing cross-relations between the signal channels are determined with due consideration of the transit-time difference. Upon the data transmission, a signal channel, the predictor coefficients and transit-time differences obtained from the cross-relations ascertained, and the prediction error are transmitted. At the receiver, the signal of the second channel is reconstructed from the transmitted signal channel, the predictor coefficients, the transit-time difference, and the prediction error. In this way, the amount of data to be transmitted in the case of multi-channel video or audio signals is reduced.
摘要翻译：在减少多信道数据传输中的数据的方法中，通过适当考虑传输时间差来确定信号信道之间现有的交叉关系。在数据传输时，发送信号信道，从确定的交叉关系获得的预测系数和传输时间差以及预测误差。在接收机处，从发射信号信道，预测器系数，传输时间差和预测误差重构第二信道的信号。以这种方式，减少了在多声道视频或音频信号的情况下要发送的数据量。

9. 发明专利

IL284276D0 Saponin conjugates 未知
公开(公告)号：IL284276D0
公开(公告)日：2021-08-31
申请号：IL28427621
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

10. 发明专利

IL284272D0 Improved cell-targeting binding molecule 未知
公开(公告)号：IL284272D0
公开(公告)日：2021-08-31
申请号：IL28427221
申请日：2021-06-21
申请人： SAPREME TECH BV , CHARITE – UNIV BERLIN , RUBEN POSTEL , HENDRIK FUCHS
发明人： RUBEN POSTEL , HENDRIK FUCHS
IPC分类号： A61K39/00 , A61K47/54 , A61K47/55 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/68 , A61P35/00 , C07H15/256 , C07J63/00 , C07K16/32
摘要： The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式